291 related articles for article (PubMed ID: 15561860)
1. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.
Offner F; Krcmery V; Boogaerts M; Doyen C; Engelhard D; Ribaud P; Cordonnier C; de Pauw B; Durrant S; Marie JP; Moreau P; Guiot H; Samonis G; Sylvester R; Herbrecht R;
Antimicrob Agents Chemother; 2004 Dec; 48(12):4808-12. PubMed ID: 15561860
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
3. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).
Cornely OA; Maertens J; Bresnik M; Ebrahimi R; Ullmann AJ; Bouza E; Heussel CP; Lortholary O; Rieger C; Boehme A; Aoun M; Horst HA; Thiebaut A; Ruhnke M; Reichert D; Vianelli N; Krause SW; Olavarria E; Herbrecht R;
Clin Infect Dis; 2007 May; 44(10):1289-97. PubMed ID: 17443465
[TBL] [Abstract][Full Text] [Related]
4. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy.
Hachem RY; Boktour MR; Hanna HA; Husni RN; Torres HA; Afif C; Kontoyiannis DP; Raad II
Cancer; 2008 Mar; 112(6):1282-7. PubMed ID: 18224662
[TBL] [Abstract][Full Text] [Related]
5. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients.
Krupova Y; Mistrik M; Bojtarova E; Sejnova D; Ilavska I; Krcmery V
Support Care Cancer; 2001 May; 9(3):209-10. PubMed ID: 11401107
[No Abstract] [Full Text] [Related]
6. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
7. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial.
Rijnders BJ; Cornelissen JJ; Slobbe L; Becker MJ; Doorduijn JK; Hop WC; Ruijgrok EJ; Löwenberg B; Vulto A; Lugtenburg PJ; de Marie S
Clin Infect Dis; 2008 May; 46(9):1401-8. PubMed ID: 18419443
[TBL] [Abstract][Full Text] [Related]
8. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
[TBL] [Abstract][Full Text] [Related]
9. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles.
De la Serna J; Jarque I; López-Jiménez J; Fernández-Navarro JM; Gómez V; Jurado M; Pascual A; Serrano J; Romero M; Vallejo C
Rev Esp Quimioter; 2013 Mar; 26(1):64-9. PubMed ID: 23546466
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients.
Bowden R; Chandrasekar P; White MH; Li X; Pietrelli L; Gurwith M; van Burik JA; Laverdiere M; Safrin S; Wingard JR
Clin Infect Dis; 2002 Aug; 35(4):359-66. PubMed ID: 12145716
[TBL] [Abstract][Full Text] [Related]
11. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
Sambatakou H; Dupont B; Lode H; Denning DW
Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
Cordonnier C; Bresnik M; Ebrahimi R
Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
[TBL] [Abstract][Full Text] [Related]
13. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice.
Wallace TL; Paetznick V; Cossum PA; Lopez-Berestein G; Rex JH; Anaissie E
Antimicrob Agents Chemother; 1997 Oct; 41(10):2238-43. PubMed ID: 9333054
[TBL] [Abstract][Full Text] [Related]
14. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
15. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B.
Denning DW; Warn P
Antimicrob Agents Chemother; 1999 Nov; 43(11):2592-9. PubMed ID: 10543734
[TBL] [Abstract][Full Text] [Related]
16. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data.
Ng TT; Denning DW
Arch Intern Med; 1995 May; 155(10):1093-8. PubMed ID: 7748054
[TBL] [Abstract][Full Text] [Related]
17. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics.
Groll AH; Gonzalez CE; Giri N; Kligys K; Love W; Peter J; Feuerstein E; Bacher J; Piscitelli SC; Walsh TJ
J Antimicrob Chemother; 1999 Jan; 43(1):95-103. PubMed ID: 10381106
[TBL] [Abstract][Full Text] [Related]
18. Changes in the natural history of invasive pulmonary aspergillosis in neutropenic leukemic patients.
Ruchlemer R; Yinnon AM; Hershko C
Isr J Med Sci; 1996 Nov; 32(11):1089-92. PubMed ID: 8960078
[TBL] [Abstract][Full Text] [Related]
19. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.
Walsh TJ; Raad I; Patterson TF; Chandrasekar P; Donowitz GR; Graybill R; Greene RE; Hachem R; Hadley S; Herbrecht R; Langston A; Louie A; Ribaud P; Segal BH; Stevens DA; van Burik JA; White CS; Corcoran G; Gogate J; Krishna G; Pedicone L; Hardalo C; Perfect JR
Clin Infect Dis; 2007 Jan; 44(1):2-12. PubMed ID: 17143808
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of caspofungin as salvage therapy for invasive aspergillosis compared to standard therapy in a historical cohort.
Hiemenz JW; Raad II; Maertens JA; Hachem RY; Saah AJ; Sable CA; Chodakewitz JA; Severino ME; Saddier P; Berman RS; Ryan DM; Dinubile MJ; Patterson TF; Denning DW; Walsh TJ
Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1387-94. PubMed ID: 20703506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
